scholarly journals Analysis of the Associations between Vitamin D and Albuminuria orβ-Cell Function in Chinese Type 2 Diabetes

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Xiaoling Cai ◽  
Zhaoheng Hu ◽  
Ling Chen ◽  
Xueyao Han ◽  
Linong Ji
Keyword(s):  
Insulin Resistance ◽  
Vitamin D ◽  
Cell Function ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Albumin Creatinine Ratio ◽  
Urine Albumin ◽  
Vitamin D Supplement ◽  
Type 2 Diabetic

Objective. To investigate the associations of 25-(OH)D andβ-cell function or insulin resistance or albuminuria in Chinese type 2 diabetic patients.Methods. In total, 1408 type 2 diabetic patients without vitamin D supplement were included in this retrospective study.Results. Comparison between patients with and without 25-(OH)D deficiency indicated that, compared with patients with 25-(OH)D ≥ 50 nmol/L, patients with 25-(OH)D < 50 nmol/L showed a higher level of urine albumin-creatinine ratio (ACR) (90.15±10.30 mg/g versus52.79±14.97 mg/g). Multiple regression analysis indicated that 25-(OH)D was independently and negatively correlated with urine ACR (OR=0.985, 95%CI 0.972–0.999,P=0.03), adjusted by age, diabetic duration, HBP duration, SBP, HbA1c, creatinine, LDL-C, triglyceride, total cholesterol, and HDL-C. Compared with patients with normal level of urine ACR, patients with higher level of urine ACR showed a significant lower level of 25-(OH)D (34.49±13.52 nmol/L versus37.46±13.6 nmol/L,P=0.00). Analysis of the associations of 25-(OH)D andβ-cell function or insulin resistance showed that 25-(OH)D may not correlate withβ-cell function or insulin resistance.Conclusion. 25-(OH)D was independently associated with albuminuria in Chinese type 2 diabetic patients but was not associated withβ-cell function or insulin resistance.

scholarly journals Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients

2011 ◽  
Vol 106 (3) ◽  
pp. 383-389 ◽  
Author(s):  
Pál Brasnyó ◽  
Gergő A. Molnár ◽  
Márton Mohás ◽  
Lajos Markó ◽  
Boglárka Laczy ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Insulin Resistance ◽  
Insulin Sensitivity ◽  
Cell Function ◽  
Diabetic Patients ◽  
Β Cell ◽  
Type 2 Diabetic Patients ◽  
Β Cell Function ◽  
Type 2 Diabetic

Although resveratrol has widely been studied for its potential health benefits, little is known about its metabolic effects in humans. Our aims were to determine whether the polyphenol resveratrol improves insulin sensitivity in type 2 diabetic patients and to gain some insight into the mechanism of its action. After an initial general examination (including blood chemistry), nineteen patients enrolled in the 4-week-long double-blind study were randomly assigned into two groups: a resveratrol group receiving oral 2 × 5 mg resveratrol and a control group receiving placebo. Before and after the second and fourth weeks of the trial, insulin resistance/sensitivity, creatinine-normalised ortho-tyrosine level in urine samples (as a measure of oxidative stress), incretin levels and phosphorylated protein kinase B (pAkt):protein kinase B (Akt) ratio in platelets were assessed and statistically analysed. After the fourth week, resveratrol significantly decreased insulin resistance (homeostasis model of assessment for insulin resistance) and urinary ortho-tyrosine excretion, while it increased the pAkt:Akt ratio in platelets. On the other hand, it had no effect on parameters that relate to β-cell function (i.e. homeostasis model of assessment of β-cell function). The present study shows for the first time that resveratrol improves insulin sensitivity in humans, which might be due to a resveratrol-induced decrease in oxidative stress that leads to a more efficient insulin signalling via the Akt pathway.

scholarly journals The study of dyslipidemia and its correlation with nephropathy in diabetes mellitus type 2 patients

2017 ◽  
Vol 4 (5) ◽  
pp. 1231
Author(s):  
Rakesh K. Sisodia ◽  
Archana Gupta ◽  
Neelima Singh
Keyword(s):  
Diabetic Nephropathy ◽  
P Value ◽  
Diabetic Patients ◽  
Creatinine Ratio ◽  
Type 2 Diabetic Patients ◽  
Albumin Creatinine Ratio ◽  
Urine Albumin ◽  
Lipid Abnormalities ◽  
Type 2 Diabetic

Background: Diabetic nephropathy is one of the most severe diabetic microangiopathies. The aim of this study was to evaluate the lipid abnormalities associated with different stages of proteinuria in type 2 diabetic patients.Methods: In this study 100 type 2 diabetic patients were subjected to detailed history, clinical examination, Serum lipid profile, urine albumin creatinine ratio and routine biochemical investigations.Results: Out of 100 patients were included in study, 41 patients were normoabluminuric, 37 patients were microalbuminuric and 22 patients were overt proteinuric. Most common dyslipidemia found in study is increased triglyceride (43%) followed by increased LDL (28). On comparing normoalbuminuric to overt proteinuric, a positive correlation found in increased triglyceride (P value < 0.001) and increases LDL (P value <0.001).Conclusions: Concluded that raised Triglyceride and LDL are associated with Diabetic Nephropathy.

Vitamin D3 supplementation improves glycemic control in type 2 diabetic patients: Results from an Italian clinical trial

2020 ◽  
pp. 1-10
Author(s):  
Giuseppe Derosa ◽  
Angela D’Angelo ◽  
Chiara Martinotti ◽  
Maria Chiara Valentino ◽  
Sergio Di Matteo ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Metabolic Control ◽  
Vitamin D3 ◽  
Therapy Group ◽  
Hypoglycemic Agents ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Type 2 Diabetic

Abstract. Background: to evaluate the effects of Vitamin D3 on glyco-metabolic control in type 2 diabetic patients with Vitamin D deficiency. Methods: one hundred and seventeen patients were randomized to placebo and 122 patients to Vitamin D3. We evaluated anthropometric parameters, glyco-metabolic control, and parathormone (PTH) value at baseline, after 3, and 6 months. Results: a significant reduction of fasting, and post-prandial glucose was recorded in Vitamin D3 group after 6 months. A significant HbA1c decrease was observed in Vitamin D3 (from 7.6% or 60 mmol/mol to 7.1% or 54 mmol) at 6 months compared to baseline, and to placebo (p < 0.05 for both). At the end of the study period, we noticed a change in the amount in doses of oral or subcutaneous hypoglycemic agents and insulin, respectively. The use of metformin, acarbose, and pioglitazone was significantly lower (p = 0.037, p = 0.048, and p = 0.042, respectively) than at the beginning of the study in the Vitamin D3 therapy group. The units of Lispro, Aspart, and Glargine insulin were lower in the Vitamin D3 group at the end of the study (p = 0.031, p = 0.037, and p = 0.035, respectively) than in the placebo group. Conclusions: in type 2 diabetic patients with Vitamin D deficiency, the restoration of value in the Vitamin D standard has led not only to an improvement in the glyco-metabolic compensation, but also to a reduced posology of some oral hypoglycemic agents and some types of insulin used.

Sign in / Sign up

Export Citation Format

Share Document